bpc 157 and tirzepatide Peptide of the Week: Tirzepatide, a Game Changer for Type 2 Diabetes Obesity Management GLP-1 medications and peptide therapies

What rodent data can't tell us: species-specific differences in NNMT expression and NAD+ salvage pathways mean rats may tolerate prolonged NNMT inhibition differently than humans

Most guys don't expect hormones to mess with their sensitivity

Dead nerves disrupt signals to and from the brain, interfering with physical and mental performance

But the reality is these substances remain experimental for good reason

AHK-Cu has been studied in this context for its possible contribution to enhancing VEGF signaling, which may in turn support fibroblast and endothelial cell activity

Extended Protocol (24 Weeks): The longest clinical trial evaluated 24-week daily administration with doses of 0.25 mg, 0.5 mg, and 1 mg